Elafibranor sustained biochemical response through week 78 in patients with primary biliary cholangitis and has a “potential beneficial effect” on itch-related quality of life, according to late-breaking data presented at EASL Congress.“There is a major unmet need for a primary biliary cholangitis (PBC) treatment that effectively targets the biochemical indicators of disease
Interim results from INTEGRIS-PSC to be featured in an oral presentation on Monday, November 13SOUTH SAN FRANCISCO, Calif., Oct. 19, 2023 Pliant Therapeutics, Inc. , a clinical-stage.
/PRNewswire/ CymaBay Therapeutics, Inc. (NASDAQ: CBAY), a clinical-stage biopharmaceutical company focused on developing therapies for liver and other.
Data from Phase 3 REGENERATE study supporting positive benefit-risk profile of obeticholic acid in liver fibrosis due to NASH to be featured in late-breaker podium presentation Analysis. | October 31, 2022